C. Clemm

2.0k total citations
35 papers, 654 citations indexed

About

C. Clemm is a scholar working on Surgery, Neurology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. Clemm has authored 35 papers receiving a total of 654 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Surgery, 11 papers in Neurology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. Clemm's work include Testicular diseases and treatments (26 papers), Neuroblastoma Research and Treatments (11 papers) and Sarcoma Diagnosis and Treatment (7 papers). C. Clemm is often cited by papers focused on Testicular diseases and treatments (26 papers), Neuroblastoma Research and Treatments (11 papers) and Sarcoma Diagnosis and Treatment (7 papers). C. Clemm collaborates with scholars based in Germany, United States and Netherlands. C. Clemm's co-authors include A. Gerl, W. Wilmanns, R. Lamerz, N. Schmeller, R. Hartenstein, Marcus Hentrich, Klaus von Werder, H. Dienemann, Hans‐Joachim Schmoll and M. Kriegmair and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and FEBS Letters.

In The Last Decade

C. Clemm

34 papers receiving 626 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Clemm Germany 16 564 233 188 167 146 35 654
Steven A. Clark United States 6 471 0.8× 157 0.7× 246 1.3× 99 0.6× 95 0.7× 8 547
Alessia Donadio United States 6 441 0.8× 186 0.8× 144 0.8× 73 0.4× 121 0.8× 8 548
Craig Nichols United States 6 382 0.7× 163 0.7× 112 0.6× 75 0.4× 118 0.8× 11 432
J.R. Germà Spain 12 385 0.7× 100 0.4× 127 0.7× 196 1.2× 83 0.6× 27 520
R. E. Drasga United States 7 388 0.7× 110 0.5× 194 1.0× 74 0.4× 198 1.4× 9 629
S. Weinknecht Germany 11 414 0.7× 100 0.4× 153 0.8× 152 0.9× 88 0.6× 14 546
K.‐P. Dieckmann Germany 17 766 1.4× 63 0.3× 210 1.1× 236 1.4× 348 2.4× 56 939
S Walbom-Jørgensen Denmark 8 280 0.5× 56 0.2× 95 0.5× 94 0.6× 112 0.8× 21 409
Vogelzang Nj United States 9 248 0.4× 103 0.4× 114 0.6× 42 0.3× 67 0.5× 12 436
P. Schmidt Germany 9 394 0.7× 157 0.7× 158 0.8× 34 0.2× 77 0.5× 14 485

Countries citing papers authored by C. Clemm

Since Specialization
Citations

This map shows the geographic impact of C. Clemm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Clemm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Clemm more than expected).

Fields of papers citing papers by C. Clemm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Clemm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Clemm. The network helps show where C. Clemm may publish in the future.

Co-authorship network of co-authors of C. Clemm

This figure shows the co-authorship network connecting the top 25 collaborators of C. Clemm. A scholar is included among the top collaborators of C. Clemm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Clemm. C. Clemm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bailey, Jonathan, C. Clemm, David P. Durham, et al.. (2021). 337: Food insecurity in the cystic fibrosis care center network during COVID-19: Prevalence, screening, and interventions. Journal of Cystic Fibrosis. 20. S161–S161. 2 indexed citations
2.
Clemm, C., Michael Souvatzoglou, Mirjam Hermisson, et al.. (2014). Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature. Experimental Hematology and Oncology. 3(1). 29–29. 4 indexed citations
3.
Steyerberg, Ewout W., A. Gerl, S.D. Fosså, et al.. (1998). Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer.. Journal of Clinical Oncology. 16(1). 269–274. 72 indexed citations
4.
Gerl, A., C. Clemm, N. Schmeller, et al.. (1997). Late relapse of germ cell tumors after cisplatin-based chemotherapy. Annals of Oncology. 8(1). 41–47. 100 indexed citations
5.
Hentrich, Marcus, N. Brack, Peter Schmid, et al.. (1996). Testicular germ cell tumors in patients with human immunodeficiency virus infection. Cancer. 77(10). 2109–2116. 24 indexed citations
6.
Gerl, A., C. Clemm, N. Schmeller, et al.. (1996). Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. British Journal of Cancer. 74(8). 1280–1285. 21 indexed citations
7.
Gerl, A., C. Clemm, R. Lamerz, & W. Wilmanns. (1996). Cisplatin-based chemotherapy of primary extragonadal germ cell tumors: A single institution experience. Cancer. 77(3). 526–532. 39 indexed citations
8.
Gerl, A., C. Clemm, R. Lamerz, & W. Wilmanns. (1996). Cisplatin‐based chemotherapy of primary extragonadal germ cell tumors: A single institution experience. Cancer. 77(3). 526–532. 3 indexed citations
9.
Gerl, A., C. Clemm, N. Schmeller, et al.. (1995). Prognosis after salvage treatment for unselected male patients with germ cell tumours. British Journal of Cancer. 72(4). 1026–1032. 33 indexed citations
10.
Gerl, A., C. Clemm, N. Schmeller, et al.. (1995). Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Annals of Oncology. 6(5). 483–488. 33 indexed citations
11.
Gerl, A., C. Clemm, Peter Köhl, & W. Wilmanns. (1994). Testicular T umor afterCisplatin-Based Chemotherapyfor Germ Cell Malignancy. European Urology. 25(3). 216–219. 8 indexed citations
12.
Gerl, A., et al.. (1994). Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer. Clinical & Experimental Metastasis. 12(3). 226–230. 24 indexed citations
13.
Gerl, A., C. Clemm, N. Schmeller, et al.. (1994). Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. British Journal of Cancer. 70(5). 960–965. 44 indexed citations
14.
Gerl, A., et al.. (1993). Testicular cancer and Hodgkin disease in the same patient. Cancer. 71(9). 2838–2840. 9 indexed citations
15.
Bokemeyer, C., Hans‐Joachim Schmoll, A. Harstrick, et al.. (1993). A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. European Journal of Cancer. 29(16). 2225–2231. 21 indexed citations
16.
Clemm, C., et al.. (1993). [Current status of therapy of CNS metastases of germ cell tumors].. PubMed. 32(3). 217–24. 3 indexed citations
17.
Harstrick, A., Hans‐Joachim Schmoll, Carsten Bokemeyer, et al.. (1991). Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma. Journal of Cancer Research and Clinical Oncology. 117(S4). S198–S202. 3 indexed citations
18.
Clemm, C., R. Hartenstein, N. Willich, Georg Ledderose, & W. Wilmanns. (1989). Combination Chemotherapy with Vinblastine, Ifosfamide and Cisplatin in Bulky Seminoma. Acta Oncologica. 28(2). 231–235. 12 indexed citations
19.
Staehler, G., et al.. (1989). Significance of Salvage Lymphadenectomy in the Therapeutical Concept of Advanced Nonseminomatous Germ Cell Tumors. Urologia Internationalis. 44(2). 84–86. 3 indexed citations
20.
Berdel, Wolfgang E., C. Clemm, R. Hartenstein, et al.. (1987). Benefit and Costs of Follow-Up Programs in Nonseminomatous Germ Cell Tumors of the Stages Ilb–IV: The Munich Experience. Oncology. 44(5). 273–278. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven A. Clark Breakdown of academic impact, for papers by Alessia Donadio Breakdown of academic impact, for papers by Craig Nichols Breakdown of academic impact, for papers by J.R. Germà Breakdown of academic impact, for papers by R. E. Drasga Breakdown of academic impact, for papers by S. Weinknecht Breakdown of academic impact, for papers by K.‐P. Dieckmann Breakdown of academic impact, for papers by S Walbom-Jørgensen Breakdown of academic impact, for papers by Vogelzang Nj Breakdown of academic impact, for papers by P. Schmidt
Rankless by CCL
2026